FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for…

CARsgen’s CT053 Receives RMAT Status from FDA for Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for…